Literature DB >> 23062656

Retinal vessel caliber is associated with the 10-year incidence of glaucoma: the Blue Mountains Eye Study.

Ryo Kawasaki1, Jie Jin Wang, Elena Rochtchina, Anne J Lee, Tien Yin Wong, Paul Mitchell.   

Abstract

PURPOSE: To examine associations between quantitatively measured retinal vessel caliber and the 10-year incidence of primary open-angle glaucoma (OAG).
DESIGN: Population-based cohort study. PARTICIPANTS: The Blue Mountains Eye Study examined 3654 persons at baseline and 2461 persons at either 5 years, 10 years, or both times. After excluding 44 subjects with OAG at baseline, 2417 participants at risk of OAG at the 5- or 10-year examinations were included.
METHODS: Retinal vessel calibers of baseline retinal photographs were measured using a computer-based program and summarized as central retinal artery and vein equivalents (CRAE, CRVE). Incident OAG was defined as the development of typical glaucomatous visual field loss combined with matching optic disc rim thinning and an enlarged cup-to-disc (C:D) ratio of >0.7 or C:D asymmetry between the 2 eyes (≥0.3) at either the 5- or 10-year examination. Generalized estimating equation models were used to account for correlation between eyes while adjusting for glaucoma risk characteristics including intraocular pressure (IOP) or ocular perfusion pressure (OPP). MAIN OUTCOME MEASURES: We assessed the 10-year incidence of OAG.
RESULTS: There were 82 persons (104 eyes) who developed incident OAG over the 10-year follow-up. After adjusting for age, sex, family history of glaucoma, smoking, diabetes, hypertension, hypercholesterolemia, body mass index, spherical equivalent refraction, and C:D ratio, narrower CRAE was associated with higher risk of incident OAG (adjusted odds ratio [OR], 1.77; 95% confidence interval [CI], 1.12-2.79, per standard deviation decrease in CRAE). This association persisted after further adjustment for IOP (adjusted OR, 1.87; 95% CI, 1.14-3.05) or OPP (adjusted OR, 1.76; 95% CI, 1.11-2.78), and remained significant when analyses were confined to eyes with IOP<20 mmHg and C:D ratio<0.6 at baseline. There were no independent associations between CRVE and incident OAG.
CONCLUSIONS: Retinal arteriolar narrowing, quantitatively measured from retinal photographs, was associated with long-term risk of OAG. These data support the concept that early vascular changes are involved in the pathogenesis of OAG and suggest that computer-based measurements of retinal vessel caliber may be useful to identify people with an increased risk of developing the clinical stage of glaucoma. FINANCIAL DISCLOSURE(S): The authors have no proprietary or commercial interest in any of the materials discussed in this article.
Copyright © 2013 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23062656     DOI: 10.1016/j.ophtha.2012.07.007

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  35 in total

1.  Comparison of subjective and objective methods to determine the retinal arterio-venous ratio using fundus photography.

Authors:  Rebekka Heitmar; Angelos A Kalitzeos; Sunni R Patel; Diana Prabhu-Das; Robert P Cubbidge
Journal:  J Optom       Date:  2014-07-26

2.  Inter-method agreement in retinal blood vessels diameter analysis between Dynamic Vessel Analyzer and optical coherence tomography.

Authors:  Lucia Benatti; Federico Corvi; Livia Tomasso; Stefano Mercuri; Lea Querques; Fulvio Ricceri; Francesco Bandello; Giuseppe Querques
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-02-11       Impact factor: 3.117

3.  Blood flow velocity vector field reconstruction from dual-beam bidirectional Doppler OCT measurements in retinal veins.

Authors:  Gerold C Aschinger; Leopold Schmetterer; Veronika Doblhoff-Dier; Rainer A Leitgeb; Gerhard Garhöfer; Martin Gröschl; René M Werkmeister
Journal:  Biomed Opt Express       Date:  2015-04-06       Impact factor: 3.732

4.  Evaluating retinal vessel diameter with optical coherence tomography in normal-tension glaucoma patients.

Authors:  Takeshi Yabana; Yukihiro Shiga; Ryo Kawasaki; Kazuko Omodaka; Hidetoshi Takahashi; Koudai Kimura; Kyosuke Togashi; Takaaki Horii; Kei Sasaki; Testuya Yuasa; Toru Nakazawa
Journal:  Jpn J Ophthalmol       Date:  2017-06-30       Impact factor: 2.447

5.  Mathematical modeling approaches in the study of glaucoma disparities among people of African and European descents.

Authors:  Giovanna Guidoboni; Alon Harris; Julia C Arciero; Brent A Siesky; Annahita Amireskandari; Austin L Gerber; Andrew H Huck; Nathaniel J Kim; Simone Cassani; Lucia Carichino
Journal:  J Coupled Syst Multiscale Dyn       Date:  2013-04-01

Review 6.  [Assessment of risk factors for the occurrence of open angle glaucoma : Guidelines of the German Ophthalmological Society and the Professional Association of Ophthalmologists in Germany].

Authors: 
Journal:  Ophthalmologe       Date:  2021-01       Impact factor: 1.059

7.  Retinal vascular caliber between eyes with asymmetric glaucoma.

Authors:  John Mark S De Leon; Carol Y Cheung; Tien-Yin Wong; Xiang Li; Haslina Hamzah; Tin Aung; Daniel Hsien-Wen Su
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-01-21       Impact factor: 3.117

Review 8.  Risk factors for open-angle glaucoma and recommendations for glaucoma screening.

Authors:  Alexander K Schuster; Felix M Wagner; Norbert Pfeiffer; Esther M Hoffmann
Journal:  Ophthalmologe       Date:  2021-04-21       Impact factor: 1.059

9.  Retinal blood flow in glaucomatous eyes with single-hemifield damage.

Authors:  Mitra Sehi; Iman Goharian; Ranjith Konduru; Ou Tan; Sowmya Srinivas; Srinivas R Sadda; Brian A Francis; David Huang; David S Greenfield
Journal:  Ophthalmology       Date:  2013-11-28       Impact factor: 12.079

10.  Retinal vessel diameter in normal-tension glaucoma patients with asymmetric progression.

Authors:  Tae-Eun Lee; Yong Yeon Kim; Chungkwon Yoo
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2014-08-12       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.